Clearmind’s novel treatment candidates are backed by rigorous science and well-defined intellectual property. Below is a deep dive into the science behind MEAI and the patents that protect it and other treatments.
MEAI holds the promise to break the vicious binge-drinking cycle by potentially innervating neural pathways such as 5-HT1A, which leads to decreased impulsivity and “sensible behaviour”.
Pre-clinical in vivo results demonstrate longtail tapering off of activity via oral administration. This may explain the self-limiting property of MEAI — unlike traditional treatments.
The literature shows that 5-HT1A receptors are associated with controlling craving behaviour across the board. This indicates that MEAI may have a wide range of applications beyond binge drinking.
MEAI was progressed through a preliminary drug development route with a number of studies:
A comparison of the complete blood count values between the treatment groups (10, 30 and 90mg/kg) to the control group, revealed no significant changes, which indicate a lack of toxicity on the hematopoietic system after 5 days of subacute MEAI exposure.
These results together with the pathological and histopathological finding indicate lack of liver and kidney toxicities in the subacute toxicity study. The combination of 6% or 7.5% ethanol with 100 mg/L MEAI revealed no statistically significant increase of cytotoxic effect.
5 days oral administration of MEAI (at a dose level of 10 and 30 mg/kg in male and female rats) did not cause any significant adverse clinical effects.
Low cytotoxicity was observedin the in vitro cytotoxicity assays3.
MEAI showed a good safety profileat 10 and 30mg/kg in rats, corresponding to the human doses of 1.6 mg/kg and 4.8 mg/kg respectively.
Ethanol-MEAI mixtures induced no synergistic/additive neurotoxicity.
Shimshoni Jacob1 and Nutt David2, et al. 2017
[1] Kimron Veterinary Institute, Department of Toxicology, Bet Dagan, Israel.
[2] Imperial College London, Neuropsychopharmacology Unit, London, UK.
Our IP portfolio consists of 16 utility patent families including 27 granted patents and 25 pending applications. The portfolio spans a wide range of jurisdictions including the US, Europe, India and China.
Links to two of our patent family filings are below.
Alcoholic Beverages Substitutes, and Binge Behaviour Regulators:
27 Granted patents in US, Europe, India, China and more
Combination treatment of Obesity and metabolic syndrome, treatment of cocaine addiction, treatment of binge behaviours, and treatment of depression. Benzufurans as Fail-Safes for MDMA Therapy, 2-FDCK for treatment of depression and TRD, combination treatment of PEA with MDMA, ibogaine, ketamine, LSD, psilocybin and DMT, 3-MMC for treatment of Dyskinesia
Pending worldwide
(2019).
Psychopharmacology
236, 989-999
.
Over the last decade, many new psychostimulant analogues have appeared on the recreational drug market and most are derivatives of amphetamine or cathinone. Another class of designer drugs is derived from the 2-aminoindan structural template. Several members of this class, including the parent compound 2-aminoindan (2-AI), have been sold as designer drugs. Another aminoindan derivative, 5-methoxy-2-aminoindan (5-MeO-AI or MEAI), is the active ingredient in a product marketed online as an alcohol substitute.
Download(2018).
Toxicology and Applied Pharmacology
343, 29-39
.
5-Methoxy-2-aminoindane (MEAI) is a novel psychoactive aminoindane derivative, exerting euphoric, alcohol-like tipsy experience and reduced desire to consume alcoholic beverages. Our previous toxicological evaluation of MEAI in rats, clearly indicated MEAI's potential to be further evaluated as a promising binge mitigating agent due to its favorable safety profile. In the light of these observations, we have determined MEAI's pharmacokinetic (PK) profile in rats and evaluated in-vitro its pharmacodynamics (PD) profile...
Download(2017).
Toxicology and Applied Pharmacology
319, 59-68
.
5-Methoxy-2-aminoindane (MEAI) is a psychoactive compound of the aminoindane class, which in recent years has been recreationally used by many people, who reported of a mild euphoric, alcohol-like tipsy experience and reduced desire to consume alcoholic beverages. In the light of these observations it was decided to progress MEAI through a preliminary drug development route and evaluate the acute and subacute toxicity of MEAI administrated orally to Sprague Dawley rats, as well as to determine potential in-vitro cytotoxic and mutagenic effects using...
Download
